FDA Approval Activities for this Drug
Targretin (bexarotene) Gel, 1%, Ligand NDA 21-056 6/28/00 7/24/00 7/24/00 7/12/01
Targretin Indications: for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
Targretin (bexarotene) capsules, 75 mg, Ligand NDA 21-055/S2 & S3 4/21/03 4/28/03
Targretin (bexarotene) capsules, 75 mg [Patient Labeling] Ligand NDA 21-055 12/29/99 1/3/00 1/3/00 4/11/02
Targretin Indication: Targretin (bexarotene) capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. | Targretin (bexarotene) Capsules, Eisai Inc., Labeling Revision | Targretin, bexarotene, Capsule; Oral, Eisai Inc, Labeling Revision
^ FDA's latest approval appears at the bottom of this list. ^